Overview

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
A clinical study to Evaluate the Safety and Efficacy of NK cells in the treatment of Myelodysplastic Syndromes
Phase:
Early Phase 1
Details
Lead Sponsor:
Nuwacell Biotechnologies Co., Ltd.
Collaborator:
The First Affiliated Hospital of University of Science and Technology of China